Sustainable Fuels, Renewable Fuel Standard (RFS) • Letters, Testimony & Comments • October 31, 2019
October 30, 2019
Docket ID: No. EPA-HQ-OAR-2019-0136
Public Hearing: Renewable Fuel Standard Program: Standards for 2020 and Biomass Based Diesel Volume for 2021, and Response to the Remand of the 2016 Standards; Supplemental...
Sustainable Fuels, Renewable Fuel Standard (RFS) • Letters, Testimony & Comments • October 31, 2019
Dear Chairman Tonko, Chairman Pallone, Ranking Member Shimkus, Ranking Member Walden, and Members of the Subcommittee:
The Biotechnology Innovation Organization (BIO) is pleased to submit a statement for the record to the to the...
Human Health • Letters, Testimony & Comments • October 30, 2019
In a recent letter, BIO’s Jim Greenwood commended Representative Steil (R-WI) for introducing the “Helping Startups Continue to Grow Act,” which extends the exemption afforded to Emerging Growth Companies under the JOBS Act from...
Sustainable Fuels, Climate Change, Renewable Fuel Standard (RFS) • Letters, Testimony & Comments • October 24, 2019
Thanks to biotechnology, advances in biofuels made from renewable resources and waste feedstocks can be used to decarbonize our roadways, seaways, and airways. In order to achieve the goal of a 100 Percent Clean Economy for this...
The Biotechnology Innovation Organization (BIO) has submitted comments to the Office of Science Technology and Policy (OSTP) on the bioeconomy, explaining the critical role America’s biotechnology industry plays in feeding,...
“What has set the U.S. biotech sector apart has been thoughtful, bipartisan public policy approaches that create a favorable climate in which to undertake the lengthy and risky job of investing in and developing the next biotech...
Dear Administrator Verma:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to commenton the Center for Medicare and Medicaid Services’ (CMS’s) CY2020 Revisions to PaymentPolicies under the Physician Fee...
Intellectual Property • Press Release • October 21, 2019
“BIO fully supports the role of CFIUS in ensuring appropriate national security screening of certain foreign investments, but any rules must not discourage the entrepreneurial spirit that has made America the global leader in...
Human Health, Orphan & Rare Diseases, Rare Diseases • Press Release • October 14, 2019
BIO’s President and CEO Jim Greenwood issued the following statement after the Congressional Budget Office released an analysis confirming that H.R. 3 will lead to fewer new medicines for patients.
